STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM's DR5 agonist antibody IGM-8444 (NCT04553692).
MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm: MVIR), through which IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells. The combination of IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) being developed by IGM, and birinapant has been shown to enhance anti-tumor activity preclinically.
Medivir AB (Nasdaq Stockholm: MVIR) announces today that the independent safety committee (IDMC) for the phase II study of birinapant in combination with pembrolizumab (Keytruda®) in patients with MSS colorectal cancer has performed the planned futility analysis. The primary objective of the phase II study was an improved clinical response to treatment measured as 20% ORR (Overall Response Rate). IDMC's recommendation is that the study should be terminated as the analysis indicates that it is unlikely that the study's objectives will be met. Medivir has therefore decided to discontinue the recruitment of patients and to end the study.
HUDDINGE, Sweden, May 16, 2019 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®) will be presented during the American Society of Clinical Oncology annual meeting, which will take place 31 May – 04 June in Chicago, USA.